Henry Schein, Inc. (HSIC) – What Are Researchers Thinking About This Stock?

Shares of Henry Schein, Inc. (NASDAQ:HSIC – Get Free Report) have received an average rating of “Moderate Buy” from the fourteen brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $93.57.

HSIC has been the subject of several research analyst reports. UBS Group raised their target price on shares of Henry Schein from $94.00 to $95.00 and gave the company a “neutral” rating in a research note on Wednesday, November 4th. Barclays reiterated an “overweight” rating and issued a $100.00 price target (up from $86.00) on shares of Henry Schein in a research note on Thursday, August 6th. Wall Street Zen raised shares of Henry Schein from a “hold” rating to a “buy” rating in a report on Monday, August 17th. BTIG Research increased their price objective on shares of Henry Schein from $100.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, August 19th. Finally, Weiss Ratings upgraded Henry Schein from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, August 21st.

View Our Latest Analysis on HSIC

Henry Schein Trading Down 1.5%

Shares of HSIC opened at $84.96 on Tuesday. The firm has a market cap of $9.39 billion, a P/E ratio of 23.28, a price-to-earnings-growth ratio of 1.51 and a beta of 0.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.33 and a quick ratio of 0.76. Henry Schein has a 1 year low of $68.70 and a 1 year high of $92.18. The company has a 50 day simple moving average of $85.81 and a two-hundred day simple moving average of $81.59.

Henry Schein (NASDAQ:HSIC – Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported $1.56 EPS for the quarter, topping the consensus estimate of $1.36 by $0.20. Henry Schein had a net margin of 3.07% and a return on equity of 16.39%. The firm had revenue of $3.47 billion for the quarter, compared to the consensus estimate of $3.48 billion. During the same quarter in the previous year, the firm earned $1.38 earnings per share. The company’s quarterly revenue was up 4.0% compared to the same quarter last year. On average, equities analysts expect that Henry Schein will post 5.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Henry Schein

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Southpoint Capital Advisors LP boosted its stake in Henry Schein by 28.0% during the first quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company’s stock valued at $235,840,000 after buying an additional 700,000 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Henry Schein by 2.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,873,004 shares of the company’s stock valued at $211,734,000 after buying an additional 56,687 shares in the last quarter. M.D. Sass LLC increased its stake in Henry Schein by 2.9% in the 1st quarter. M.D. Sass LLC now owns 1,273,316 shares of the company’s stock worth $93,843,000 after acquiring an additional 35,443 shares during the last quarter. Bank of America Corp DE increased its stake in Henry Schein by 5.9% in the 1st quarter. Bank of America Corp DE now owns 1,221,585 shares of the company’s stock worth $90,031,000 after acquiring an additional 68,593 shares during the last quarter. Finally, Defilade Capital Management L.P. raised its holdings in shares of Henry Schein by 94.8% during the 1st quarter. Defilade Capital Management L.P. now owns 624,037 shares of the company’s stock worth $45,992,000 after acquiring an additional 303,615 shares in the last quarter. 96.62% of the stock is owned by institutional investors.

Henry Schein Company Profile

(Get Free Report)

Henry Schein, Inc. is a global distributor of health care products and services, serving dental and medical practitioners, veterinary professionals, and other health care organizations. The company traces its roots to a pharmacy founded by Henry and Esther Schein in Queens, New York, in 1932. Its offerings include medical and dental supplies, equipment, pharmaceuticals, vaccines, and diagnostic products. Henry Schein also provides practice-management software, technology solutions, and business services designed to help health care professionals manage their operations.

Featured Articles

Analyst Recommendations for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.